Meeting
2022 ASCO Genitourinary Cancers Symposium
Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience.
Authors
Andrew Warren Hahn
The University of Texas MD Anderson Cancer Center, Houston, TX
Andrew Warren Hahn , Paul Vincent Viscuse , Devaki Shilpa Surasi , Tharakeswara Bathala , Andrew James Wiele , Michael W Starbuck , Matthew T Campbell , Amishi Yogesh Shah , Eric Jonasch , Jianjun Gao , Omar Alhalabi , Kanishka Sircar , Nizar M. Tannir , Pavlos Msaouel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 351)
DOI
10.1200/JCO.2022.40.6_suppl.351
Abstract #
351
Poster Bd #
G2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst
Poster
2012 Genitourinary Cancers Symposium
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).
First Author: Daniel Yick Chin Heng
Poster
2024 ASCO Genitourinary Cancers Symposium
Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.
First Author: Mehul Gupta
Poster
2023 ASCO Annual Meeting
Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies.
First Author: Arthur Geraud